Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

European Innovation Council · Running

M4GIC-ILC ​Multi-modal, Multi-site, Multi-omic, Multi-AGent AI framework for the Clinical management of ILC

Coordinator
Katholieke Universiteit Leuven, Belgium
Runs
1 October 2026 to 30 September 2029
Status
Running
EU funding
€4.0m
Total cost
—
Partners
6 organisations in 6 countries
Type
European Innovation Council
Grant agreement
101306757

What the project is doing

In the project's own words, from its summary on CORDIS.

Invasive lobular carcinoma (ILC) is the second most common histological subtype of breast cancer, yet it remains underrepresented in clinical trials due to its distinct clinical course and metastatic behavior. Radiological detection of ILC is particularly challenging, as lesions often present with low contrast and diffuse infiltration. In pathology, overlapping morphological features between classic and non-classic ILC and other breast cancer subtypes lead to diagnostic uncertainty and high inter-pathologist variability.

These limitations extend to molecular assays and AI models, which have largely been trained on cohorts with low ILC representation and typically underperform for this subtype. M4GIC-ILC—a Multi-modal, Multi-site, Multi-omic, Multi-AGent AI framework for the clinical management of ILC—addresses these challenges by unifying representation learning, generative AI, and supervised prediction across pathology, radiology, molecular, and clinical data.

Foundation-model backbones are fine-tuned for ILC to learn batch-aware, biologically grounded embeddings, while generative AI provides calibrated proxies for missing modalities (virtual IHC, virtual MGS, and imaging views), enabling clinicians to interpret cases in familiar diagnostic settings. On top, task-specific predictors estimate diagnosis (ILC vs other; classic vs non-classic), staging (T/N, focality, laterality), relapse risk, and treatment benefit (endocrine, CDK4/6i, chemotherapy), with calibrated uncertainty and abstention when confidence is low.

The framework is orchestrated by a multi-agent system that integrates these tools into interactive, natural-language reports with visual explanations and full provenance. Development and validation occur through federated learning on a harmonized, FAIR multisite repository. M4GIC-ILC will bridge the current diagnostic and therapeutic gap in ILC, delivering trustworthy, explainable AI that improves patient stratification and personalizes breast cancer care.

Topics

Who is involved

OrganisationCityCountryRole
Katholieke Universiteit LeuvenLeuvenBelgiumCoordinator
Accelopment Schweiz AGZurichSwitzerlandParticipant
Panepistimio KritisRethimnoGreeceParticipant
Institut CurieParisFranceParticipant
Universitair Medisch Centrum UtrechtUtrechtNetherlandsParticipant
Collective Minds Radiology ABDanderydSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI